MX2016002539A - Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion. - Google Patents

Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.

Info

Publication number
MX2016002539A
MX2016002539A MX2016002539A MX2016002539A MX2016002539A MX 2016002539 A MX2016002539 A MX 2016002539A MX 2016002539 A MX2016002539 A MX 2016002539A MX 2016002539 A MX2016002539 A MX 2016002539A MX 2016002539 A MX2016002539 A MX 2016002539A
Authority
MX
Mexico
Prior art keywords
fab
present
poly
serum albumin
effector fusion
Prior art date
Application number
MX2016002539A
Other languages
English (en)
Other versions
MX371328B (es
Inventor
Sanghoon Cha
Original Assignee
Aprilbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprilbio Co Ltd filed Critical Aprilbio Co Ltd
Publication of MX2016002539A publication Critical patent/MX2016002539A/es
Publication of MX371328B publication Critical patent/MX371328B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al fragmento (Fab) de unión a antígeno y proteína de fusión o (poli) péptido efectores de Fab que lo comprenden. El Fab de la presente invención específicamente se une a albúmina de suero y por lo tanto tiene una vida media in vivo prolongada. El Fab de la presente invención se caracteriza por no tener residuos de cisteína que son responsables del enlace de disulfuro intercadena en el dominio CH1 y el dominio CKL también. La proteína de fusión o (poli) péptido efectores de Fab de la presente invención pueden producirse en periplasma de E. coli con alto rendimiento, y tiene una vida media in vivo aumentada. Adicionalmente, la presente invención provee la cepa E. coli que produce varias clases de proteínas de fusión o (poli) péptidos efectores de Fab, y una composición farmacéutica que comprende las proteínas de fusión o (poli)péptidos efectores de Fab.
MX2016002539A 2013-08-30 2014-08-29 Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion. MX371328B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130104112 2013-08-30
PCT/KR2014/008106 WO2015030539A1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof

Publications (2)

Publication Number Publication Date
MX2016002539A true MX2016002539A (es) 2016-10-13
MX371328B MX371328B (es) 2020-01-27

Family

ID=52586989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002539A MX371328B (es) 2013-08-30 2014-08-29 Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.

Country Status (17)

Country Link
US (2) US9879077B2 (es)
EP (2) EP3632930A1 (es)
JP (2) JP6422977B2 (es)
KR (2) KR101576561B1 (es)
CN (1) CN105899532B (es)
AU (1) AU2014312456B2 (es)
BR (1) BR112016004355A2 (es)
CA (1) CA2922618C (es)
DK (1) DK3039038T3 (es)
ES (1) ES2866848T3 (es)
HK (1) HK1223107A1 (es)
MX (1) MX371328B (es)
PH (1) PH12016500403A1 (es)
PL (1) PL3039038T3 (es)
RU (1) RU2661087C2 (es)
UA (1) UA117493C2 (es)
WO (1) WO2015030539A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
CN113166266A (zh) * 2018-06-18 2021-07-23 安维塔生物科学股份有限公司 抗间皮素构建体及其用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
WO2023242251A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Follistatin-fc fusion proteins
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
ATE328906T1 (de) * 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
US20080181892A1 (en) * 2004-08-11 2008-07-31 Trubion Pharmaceuticals Binding Domain Fusion Protein
EP1796718A2 (en) * 2004-10-05 2007-06-20 Genentech, Inc. Therapeutic agents with decreased toxicity
EP2024396A2 (en) * 2004-12-02 2009-02-18 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
CN101155832B (zh) * 2005-02-08 2013-02-06 一般财团法人化学及血清疗法研究所 抗体的改良方法
JP2010528664A (ja) * 2007-06-08 2010-08-26 ダウ グローバル テクノロジーズ インコーポレイティド Ｃｈ１ドメインの切断による可溶性抗体断片の発現
EP2535349A1 (en) * 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CN102057054B (zh) * 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2010063818A2 (en) 2008-12-05 2010-06-10 Glaxo Group Limited Methods for selecting protease resistant polypeptides
CN105963710A (zh) * 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2483308A1 (en) * 2009-09-30 2012-08-08 Glaxo Group Limited Drug fusions and conjugates with extended half life
CN107936121B (zh) * 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
SG11201401649VA (en) * 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof

Also Published As

Publication number Publication date
BR112016004355A2 (pt) 2017-10-17
EP3039038A4 (en) 2017-07-05
CN105899532B (zh) 2021-10-08
JP6800180B2 (ja) 2020-12-16
EP3632930A1 (en) 2020-04-08
US9879077B2 (en) 2018-01-30
JP6422977B2 (ja) 2018-11-14
HK1223107A1 (zh) 2017-07-21
US20160376350A1 (en) 2016-12-29
PH12016500403A1 (en) 2016-05-16
US10618953B2 (en) 2020-04-14
WO2015030539A1 (en) 2015-03-05
PL3039038T3 (pl) 2021-04-19
JP2018172391A (ja) 2018-11-08
CA2922618C (en) 2020-04-28
MX371328B (es) 2020-01-27
UA117493C2 (uk) 2018-08-10
US20180030127A1 (en) 2018-02-01
KR20150026997A (ko) 2015-03-11
CN105899532A (zh) 2016-08-24
JP2016528922A (ja) 2016-09-23
KR20150118565A (ko) 2015-10-22
ES2866848T3 (es) 2021-10-19
AU2014312456A8 (en) 2016-03-17
EP3039038A1 (en) 2016-07-06
AU2014312456A1 (en) 2016-03-03
CA2922618A1 (en) 2015-03-05
EP3039038B1 (en) 2020-11-25
AU2014312456B2 (en) 2017-07-06
RU2661087C2 (ru) 2018-07-11
KR101576561B1 (ko) 2015-12-10
RU2016105586A (ru) 2017-10-04
DK3039038T3 (da) 2021-02-08

Similar Documents

Publication Publication Date Title
PH12016500403A1 (en) An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
EA201591700A1 (ru) Гибридные белки апелина и их применение
MX2014005108A (es) Constructos de polipeptidos y sus usos.
EP3929217A3 (en) Specific sites for modifying antibodies to make immunoconjugates
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
MX2015009547A (es) Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo.
SG10201805039UA (en) Protease resistant peptides
EA201790946A1 (ru) Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы
WO2014152831A3 (en) Targeting peptides and uses thereof
NZ744289A (en) Composition containing amino acids
WO2012136792A3 (en) Cck compositions
AU2016274890A8 (en) Immunoglobulin fusion proteins and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration